Apoptosis and chemotherapy for bladder cancer

被引:49
作者
McKnight, JJ
Gray, SB
O'Kane, HF
Johnston, SR
Williamson, KE
机构
[1] Belfast City Hosp, Dept Urol, Belfast BT9 7AB, Antrim, North Ireland
[2] Queens Univ Belfast, Urooncol Grp, Belfast, Antrim, North Ireland
关键词
bladder; bladder neoplasms; apoptosis; chemotherapy;
D O I
10.1097/01.ju.0000143194.79287.a9
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We discuss the role of apoptosis, that is gene directed self-destruction of a cell, in the response of bladder transitional cell carcinoma cells to chemotherapy. Materials and Methods: A directed MEDLINE literature search of apoptosis, bladder cancer and chemotherapy was performed to extract relevant information for review. The characteristics of apoptotic cells were defined and the methods in common use to detect these traits is described. The role of the key mediators of the apoptotic process in bladder cancer is discussed in the context of chemosensitivity and disease stage. The importance of the apoptosis induction after chemotherapy is highlighted. Results: On stimulus by appropriate external or internal signals a cell may alter the expression of genes encoding for proteins associated with the apoptotic process. The development of apoptosis depends on the balance between pro-apoptotic and anti-apoptotic proteins. Key alterations in genes and proteins related to apoptosis within bladder cancer result in a shift away from the default state of apoptosis toward a cell with increased survival properties that is chemoresistant. Conclusions: Much current research in bladder cancer is aimed at restoring chemosensitivity by shifting the cell toward a pro-apoptotic phenotype. Successful translation of this work into clinical practice may improve survival in patients in whom prognosis is currently poor.
引用
收藏
页码:683 / 690
页数:8
相关论文
共 75 条
[1]   The p53 network [J].
Agarwal, ML ;
Taylor, WR ;
Chernov, MV ;
Chernova, OB ;
Stark, GR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (01) :1-4
[2]   p53 mutations in urinary bladder cancer [J].
Berggren, P ;
Steineck, G ;
Adolfsson, J ;
Hansson, J ;
Jansson, O ;
Larsson, P ;
Sandstedt, B ;
Wijkström, H ;
Hemminki, K .
BRITISH JOURNAL OF CANCER, 2001, 84 (11) :1505-1511
[3]  
Boersma AWM, 1996, CYTOMETRY, V24, P123, DOI 10.1002/(SICI)1097-0320(19960601)24:2<123::AID-CYTO4>3.0.CO
[4]  
2-K
[5]   Nuclear accumulation of mutant p53 protein: A possible predictor of failure of intravesical therapy in bladder cancer [J].
Caliskan, M ;
Turkeri, LN ;
Mansuroglu, B ;
Toktas, G ;
Aksoy, B ;
Unluer, E ;
Akdas, A .
BRITISH JOURNAL OF UROLOGY, 1997, 79 (03) :373-377
[6]   Gene silencing by double-stranded RNA [J].
Carthew, RW .
CURRENT OPINION IN CELL BIOLOGY, 2001, 13 (02) :244-248
[7]   Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression [J].
Chopin, D ;
Barei-Moniri, R ;
Maillé, P ;
Le Frère-Belda, MA ;
Muscatelli-Groux, B ;
Merendino, N ;
Lecerf, L ;
Stoppacciaro, A ;
Velotti, F .
AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (04) :1139-1149
[8]   Enhanced chemosensitivity of bladder cancer cells to cisplatin by suppression of clusterin in vitro [J].
Chung, J ;
Kwak, C ;
Jin, RJ ;
Lee, CH ;
Lee, KH ;
Lee, SE .
CANCER LETTERS, 2004, 203 (02) :155-161
[9]  
Cote RJ, 1997, NATURE, V385, P123, DOI 10.1038/385123b0
[10]  
Dahse R, 2000, ONCOL REP, V7, P931